## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 1.58 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($235.23)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company**
- Source: Simply Wall Street | 20260102T140756 | Somewhat-Bullish | Relevance: 100%
- Institutional owners hold 69% of ResMed Inc. (NYSE:RMD), signifying their strong influence on the company's stock price and decisions. The Vanguard Group, Inc. is the largest shareholder with 14%, while insiders own less than 1% of the company. These holdings suggest that ResMed's stock performance is highly sensitive to institutional trading actions.

**2. ResMed (RMD) Product Pipeline Analysis Report 2025 â€“ ResearchAndMarkets.com**
- Source: The AI Journal | 20251231T163517 | Somewhat-Bullish | Relevance: 100%
- This report from ResearchAndMarkets.com provides a comprehensive analysis of ResMed Inc.'s product pipeline as of 2025. It details the company's portfolio of medical equipment for respiratory disorders, including CPAP devices, along with in-development products across various stages. The report aims to offer actionable intelligence for decision-making and competitive strategy in the medical device market.

**3. ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company**
- Source: Simply Wall Street | 20260102T135522 | Bullish | Relevance: 100%
- Institutional investors hold 69% of ResMed Inc. (NYSE:RMD), making them the most powerful shareholder group. This significant institutional ownership suggests that the stock's price is highly sensitive to their trading activities and typically indicates credibility among professional investors, though it doesn't guarantee against poor investments. The Vanguard Group, Inc. is the largest institutional shareholder with 14% of shares outstanding.

**4. ResMed Inc. $RMD Shares Sold by Inspire Investing LLC**
- Source: MarketBeat | 20260101T104841 | Neutral | Relevance: 100%
- Inspire Investing LLC significantly reduced its stake in ResMed Inc. (NYSE: RMD) by 95.6% during the third quarter, leaving them with 836 shares valued at $229,000. While some institutional investors increased their holdings, others, like Inspire Investing, sold off part of their ResMed shares. The article also details ResMed's financial performance, recent dividend announcement, and insider trading activity, alongside analyst ratings.

**5. The Truth About ResMed Inc: Is This Sleep Tech Stock Quietly Going Viral?**
- Source: AD HOC NEWS | 20260101T025049 | Somewhat-Bullish | Relevance: 100%
- ResMed Inc., a leading sleep-tech company, is gaining traction not just among medical professionals but also on social media platforms like TikTok, YouTube, and traditional finance forums. This article explores whether ResMed's focus on sleep health, data-driven technology, and recent market recovery makes it a valuable long-term healthcare investment, especially considering its competition and the potential impact of weight-loss drugs.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Stifel | $260 | $270 | -4% |
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Stifel | main | Hold |
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 15 ($4.98M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- New product launch cycle could drive revenue acceleration.
- Momentum building: MRS_10 improving +3.2% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.58 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.7B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.58 |
| Forward P/E | 20.4 |
| Current P/E | 22.4 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -2.2% to 1.0% (+3.2% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.3% confirms short-term momentum alignment. Below SMA200 (0.96x), long-term trend not supportive. RSI neutral at 45. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.00% (CS: 57) | Neutral |
| RSI_14 | 45.2 | Neutral |
| MACD Histogram | -0.19 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 0.979x | Below |
| vs SMA200 | 0.962x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $244.81
- **Stop Loss:** $235.23 (3.9% risk)
- **Target:** $254.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 150
- **Position Value:** $36,721.50
- **Portfolio %:** 36.72%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_10*